Dovato Shortage Update: What Patients Need to Know in 2026

If you rely on Dovato (dolutegravir/lamivudine) to manage your HIV, and you've had trouble filling your prescription recently, you're not alone in wondering: is there a Dovato shortage? This article provides the most current information available, explains what's really happening with Dovato availability, and gives you clear steps to protect your treatment continuity.

Dovato Shortage Status as of Early 2026

As of early 2026, Dovato is NOT listed on the FDA's official drug shortage database. ViiV Healthcare continues to manufacture and distribute Dovato normally. There are no known disruptions to the manufacturing supply chain.

However — and this is important — "not in shortage" does not mean "available at every pharmacy." For a specialty drug like Dovato, the access challenges patients experience are real, even without an FDA-declared shortage. Understanding the difference helps you navigate the system more effectively.

What Does "Not in Shortage" Actually Mean?

The FDA declares a drug shortage when a manufacturer cannot meet national demand — typically due to manufacturing defects, raw material shortages, facility issues, or a surge in demand. A shortage listing means there literally isn't enough of the drug in the supply chain.

With Dovato, ViiV Healthcare is producing enough supply to meet demand. The access challenges come from how specialty drugs move through the distribution system — not from a production shortfall. Individual pharmacies simply may not have it on their shelves.

Why Patients Still Struggle to Fill Dovato

Even without a formal shortage, several structural factors make Dovato harder to access than a typical medication:

• Specialty medication stocking practices. With a retail price of $2,000–$3,700 per month, most retail pharmacies order Dovato only on demand, not proactively. This causes 1–3 day delays even at large chains.
• No generic on the market. The fixed-dose combination of dolutegravir and lamivudine has no generic equivalent in the United States as of 2026, limiting the number of supply sources.
• Prior authorization requirements. Many insurance plans require PA before covering Dovato, which can delay access by days or longer even when the pharmacy has stock.
• Lower stock priority versus Biktarvy. Biktarvy is the most prescribed HIV medication in the US and dominates pharmacy shelf space. Pharmacies serving fewer HIV patients may stock Biktarvy but not Dovato.

Has Dovato Ever Been in a True Shortage?

Since its FDA approval on April 8, 2019, Dovato has not been placed on the FDA's official drug shortage list. ViiV Healthcare has maintained consistent manufacturing. The drug's access challenges have been distribution-related — a function of specialty pharmacy supply chains — rather than a manufacturing crisis.

This is different from drugs like some ADHD medications or GLP-1 agonists, which have experienced true FDA-declared shortages due to demand far exceeding production capacity.

What About a Generic Dovato?

As of 2026, no generic version of the fixed-dose Dovato tablet is available in the United States. The drug's patent protection is expected to remain in force until approximately 2031. Once generic manufacturers enter the market, availability and pricing will likely improve significantly — as has happened with older antiretroviral drugs. Until then, patients must work with the brand-only product from ViiV Healthcare.

Steps to Protect Your Dovato Access Right Now

Even without a national shortage, proactive planning is essential for patients on specialty HIV medications. Here's what you can do today:

1. Use medfinder (medfinder.com) to locate pharmacies near you with Dovato in stock.
2. Switch to a specialty or HIV-focused pharmacy that maintains dedicated antiretroviral inventory.
3. Refill early — at least 7–10 days before your last tablet.
4. Ensure your prior authorization is active and not pending renewal before you need your refill.
5. Contact ViiV Connect at 1-844-588-3288 if you are having difficulty obtaining Dovato — they can provide pharmacy referrals and emergency support.

The Bottom Line

Dovato is not in a national shortage in 2026. But it isn't always easy to fill, either. The access challenges are real — they're just structural rather than a production crisis. With the right tools and a bit of planning, most patients can stay on their medication without interruption. For more detail on why this drug can be hard to find, see our guide on why Dovato is hard to find in 2026.